Premium Nahrungsergänzungsmittel | artgerecht

Nintedanib: Uses, Mechanism & Side Effects

Nintedanib is a prescription tyrosine kinase inhibitor used to treat pulmonary fibrosis and certain types of cancer. It slows disease progression by blocking key growth factor receptors.

Regular tips about health Regular tips about health

Things worth knowing about "Nintedanib"

Nintedanib is a prescription tyrosine kinase inhibitor used to treat pulmonary fibrosis and certain types of cancer. It slows disease progression by blocking key growth factor receptors.

What is Nintedanib?

Nintedanib is a tyrosine kinase inhibitor (TKI) used as a targeted therapy for several serious lung conditions and certain cancers. It is marketed under the brand names Ofev® (for pulmonary fibrosis) and Vargatef® (for lung cancer). Nintedanib belongs to a class of drugs known as targeted therapies, which work by interfering with specific molecular signals that drive disease progression.

Indications

Nintedanib is approved for the following conditions:

Idiopathic Pulmonary Fibrosis (IPF): A chronic, progressive scarring of the lungs with no known cause.
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Lung involvement in patients with the connective tissue disease scleroderma.
Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype (PF-ILD): A broader group of fibrosing lung diseases that worsen over time.
Non-Small Cell Lung Cancer (NSCLC): In combination with docetaxel after failure of first-line therapy.

Mechanism of Action

Nintedanib works by blocking specific growth factor receptors that play a central role in tissue scarring (fibrosis) and the formation of new blood vessels (angiogenesis). It simultaneously inhibits the following receptor tyrosine kinases:

FGFR 1, 2, and 3 (Fibroblast Growth Factor Receptors)
VEGFR 1, 2, and 3 (Vascular Endothelial Growth Factor Receptors)
PDGFR α and β (Platelet-Derived Growth Factor Receptors)

By inhibiting these signaling pathways, nintedanib reduces the activation and proliferation of fibroblasts – the cells responsible for the excessive production of scar tissue in fibrotic diseases. In cancer, this mechanism also impairs tumor growth and metastasis by cutting off the tumor's blood supply.

Dosage and Administration

Nintedanib is taken orally as soft gelatin capsules. The standard recommended doses are:

150 mg twice daily (morning and evening, approximately 12 hours apart) for pulmonary fibrosis indications.
200 mg twice daily in combination with docetaxel chemotherapy for NSCLC.

Capsules should be taken with food to improve gastrointestinal tolerability. Dose reductions may be required in cases of significant side effects or hepatic impairment.

Side Effects

The most common side effects of nintedanib include:

Diarrhea – very common, affecting the majority of patients
Nausea and vomiting
Abdominal pain
Elevated liver enzymes (hepatotoxicity)
Decreased appetite and weight loss
High blood pressure (hypertension)
Bleeding tendencies (e.g., nosebleeds)

Less common but serious adverse events include arterial thromboembolic events (such as heart attack or stroke) and gastrointestinal perforation. Regular monitoring by a healthcare professional is essential throughout treatment.

Contraindications and Drug Interactions

Nintedanib should not be used in patients with:

Known hypersensitivity to the active substance
Pregnancy or breastfeeding (effective contraception is mandatory during treatment)
Severe hepatic impairment

Important drug interactions include:

P-glycoprotein inducers (e.g., rifampicin, carbamazepine, St. John's Wort): may significantly reduce nintedanib plasma concentrations and efficacy.
Anticoagulants: increased risk of bleeding when used concomitantly.

Clinical Significance

Nintedanib represents one of only a few approved treatment options for patients with idiopathic pulmonary fibrosis, a condition with historically very limited therapeutic choices. Clinical trials have demonstrated that nintedanib can significantly slow the decline in lung function as measured by forced vital capacity (FVC). Treatment is always initiated and supervised by a specialist and requires regular monitoring of liver function, renal function, and lung parameters.

References

European Medicines Agency (EMA): EPAR - Ofev (Nintedanib). https://www.ema.europa.eu (accessed 2024)
Richeldi L, du Bois RM, Raghu G et al. - Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014; 370(22): 2071-2082.
Distler O, Highland KB, Gahlemann M et al. - Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. New England Journal of Medicine, 2019; 380(26): 2518-2528.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.